Evidence map›Paper›PMID 36234691›Full record

ArticleMolecules (Basel, Switzerland)2022

β-Caryophyllene: A Therapeutic Alternative for Intestinal Barrier Dysfunction Caused by Obesity.

Uriel Ulises Rodríguez-Mejía, Juan Manuel Viveros-Paredes, Adelaida Sara Minia Zepeda-Morales, Lucrecia Carrera-Quintanar, José Sergio Zepeda-Nuño, Gilberto Velázquez-Juárez, Vidal Delgado-Rizo, Trinidad García-Iglesias, Luisa Guadalupe Camacho-Padilla, Elizabeth Varela-Navarro and 3 more

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Investigating the Potential of Essential Oils fromPlants (Basel, Switzerland) · 2024
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Uriel Ulises Rodríguez-MejíaLaboratorio de Investigación y Desarrollo Farmacéutico, Departamento de Farmacobiología, Centro Universitario de Ciencias Exactas e Ingenierías, Universidad de Guadalajara, Guadalajara 44430, Jalisco, Mexico.ORCID 0000-0002-8335-5071
Juan Manuel Viveros-ParedesLaboratorio de Investigación y Desarrollo Farmacéutico, Departamento de Farmacobiología, Centro Universitario de Ciencias Exactas e Ingenierías, Universidad de Guadalajara, Guadalajara 44430, Jalisco, Mexico.ORCID 0000-0002-7532-5614
Adelaida Sara Minia Zepeda-MoralesLaboratorio de Análisis Quimícos Clínicos y Bacteriológicos Vinculación, Departamento de Farmacobiología, Centro Universitario de Ciencias Exactas e Ingenierías, Universidad de Guadalajara, Guadalajara 44430, Jalisco, Mexico.
Lucrecia Carrera-QuintanarLaboratorio de Ciencias de los Alimentos, Departamento de Reproducción Humana, Crecimiento y Desarrollo Infantil, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44350, Jalisco, Mexico.ORCID 0000-0003-1947-4276
José Sergio Zepeda-NuñoDepartamento de Microbiología y Patología, Centro de Investigación y Diagnóstico de Patología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44350, Jalisco, Mexico.
Gilberto Velázquez-JuárezLaboratorio de Bioquimíca Estructural, Departamento de Química, Universidad de Guadalajara, Centro Universitario de Ciencias Exactas e Ingenierías, Universidad de Guadalajara, Guadalajara 44430, Jalisco, Mexico.ORCID 0000-0002-1130-4021
Vidal Delgado-RizoDepartamento de Fisiología, Centro de Investigación en Inmunología y Dermatología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44350, Jalisco, Mexico.
Trinidad García-IglesiasDepartamento de Fisiología, Instituto de Investigación en Cáncer de la Infancia y Adolescencia, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44350, Jalisco, Mexico.
Luisa Guadalupe Camacho-PadillaLaboratorio de Investigación y Desarrollo Farmacéutico, Departamento de Farmacobiología, Centro Universitario de Ciencias Exactas e Ingenierías, Universidad de Guadalajara, Guadalajara 44430, Jalisco, Mexico.
Elizabeth Varela-NavarroLaboratorio de Análisis Quimícos Clínicos y Bacteriológicos Vinculación, Departamento de Farmacobiología, Centro Universitario de Ciencias Exactas e Ingenierías, Universidad de Guadalajara, Guadalajara 44430, Jalisco, Mexico.
Luis Alberto Anguiano-SevillaLaboratorio de Biología Molecular, Genética y Proteómica, Instituto Transdiciplinar de Investigación y Servicios, Centro Universitario de Ciencias Exactas e Ingenierías, Universidad de Guadalajara, Guadalajara 45150, Jalisco, Mexico.ORCID 0000-0002-4213-0212
Esmeralda Marisol Franco-TorresLaboratorio de Investigación y Desarrollo Farmacéutico, Departamento de Farmacobiología, Centro Universitario de Ciencias Exactas e Ingenierías, Universidad de Guadalajara, Guadalajara 44430, Jalisco, Mexico.
Rocio Ivette López-RoaLaboratorio de Investigación y Desarrollo Farmacéutico, Departamento de Farmacobiología, Centro Universitario de Ciencias Exactas e Ingenierías, Universidad de Guadalajara, Guadalajara 44430, Jalisco, Mexico.ORCID 0000-0002-2339-4108
Universidad de Guadalajara · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obesity is an excessive accumulation of fat that exacerbates the metabolic and inflammatory processes. Studies associate these processes with conditions and dysregulation in the intestinal tract, increased concentrations of lipopolysaccharides (LPSs) in the blood, differences in the abundance of intestinal microbiota, and the production of secondary metabolites such as short-chain fatty acids. β-Caryophyllene (BCP) is a natural sesquiterpene with anti-inflammatory properties and with the potential purpose of fighting metabolic diseases. A diet-induced obesity model was performed in 16-week-old C57BL/6 mice administered with BCP [50 mg/kg]. A reduction in the expression of Claudin-1 was observed in the group with a high-fat diet (HFD), which was caused by the administration of BCP; besides BCP, the

Indexed as

Gastrointestinal DiseasesIntestinal Barrier FunctionPolycyclic SesquiterpenesAnimalsClaudin-1Diet, High-FatDisease Models, AnimalFatty AcidsLeptinMiceMice, Inbred C57BLObesitycaryophylleneClaudin-1Fatty AcidsLeptinPolycyclic Sesquiterpenesdysbiosisobesityβ-caryophyllene

Identifiers

PMID36234691
PMCPMC9570618
OpenAlexW4296743030

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.